Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 131,938 shares of the medical research company's stock after selling 6,817 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Edwards Lifesciences were worth $9,767,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth $3,173,000. World Investment Advisors LLC boosted its position in shares of Edwards Lifesciences by 1,660.7% in the 3rd quarter. World Investment Advisors LLC now owns 72,277 shares of the medical research company's stock worth $4,770,000 after purchasing an additional 68,172 shares in the last quarter. Wilmington Savings Fund Society FSB grew its stake in Edwards Lifesciences by 147.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company's stock worth $601,000 after buying an additional 5,420 shares during the last quarter. Destination Wealth Management increased its position in Edwards Lifesciences by 2.8% during the 3rd quarter. Destination Wealth Management now owns 7,012 shares of the medical research company's stock valued at $463,000 after buying an additional 193 shares in the last quarter. Finally, Tidal Investments LLC increased its position in Edwards Lifesciences by 0.7% during the 3rd quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company's stock valued at $2,609,000 after buying an additional 275 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the sale, the vice president now directly owns 47,206 shares of the company's stock, valued at $3,295,450.86. The trade was a 16.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock worth $5,163,062 over the last quarter. 0.34% of the stock is owned by corporate insiders.

Analyst Ratings Changes

EW has been the topic of several recent analyst reports. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Truist Financial cut their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $79.25.

Edwards Lifesciences Trading Up 6.7 %

EW traded up $4.69 during midday trading on Thursday, hitting $75.15. The company's stock had a trading volume of 11,705,304 shares, compared to its average volume of 4,982,174. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25. The firm has a 50-day moving average price of $70.93 and a two-hundred day moving average price of $71.02. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $44.18 billion, a P/E ratio of 10.78, a PEG ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. During the same period last year, the company posted $0.66 EPS. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.